SELLAS Life Sciences (SLS) EBITDA (2011 - 2026)

SELLAS Life Sciences (SLS) has 14 years of EBITDA data on file, last reported at -$9.3 million in Q1 2026.

• On a quarterly basis, EBITDA fell 52.6% year-over-year to -$9.3 million in Q1 2026; TTM through Mar 2026 was -$31.5 million, a 12.65% decrease from a year earlier, with the FY2025 full-year figure at -$28.3 million, up 10.28% from the prior year.
• EBITDA for Q1 2026 stood at -$9.3 million, down from -$8.3 million in the prior quarter.
• Over the last five years, EBITDA for SLS reached as high as -$6.1 million in Q1 2025 and fell as low as -$16.7 million in Q1 2022.
• Historically, EBITDA has averaged -$8.8 million across 5 years, with a median of -$8.3 million in 2025.
• Across the five-year window, EBITDA sank 645.43% in 2022 and soared 37.14% in 2025, its largest moves.
• Year by year, EBITDA stood at -$9.4 million in 2022, then advanced by 13.43% to -$8.2 million in 2023, then grew by 15.4% to -$6.9 million in 2024, then declined by 19.33% to -$8.3 million in 2025, then retreated by 12.08% to -$9.3 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$9.3 million in Q1 2026, -$8.3 million in Q4 2025, and -$7.1 million in Q3 2025.